GSM8262869: PDAC validation experiment 1, D7, row 6, hash; Homo sapiens; RNA-Seq
Patient-derived pancreatic cancer (PDAC) organoids were derived as previously described from patients with metastatic pancreatic cancer (Raghavan et al., Cell, 2021) and cultured in Growth factor Reduced Matrigel, fed with human complete organoid medium (Advanced DMEM/F12, 10 mM HEPES, 1x GlutaMAX, 500 nM A83-01, 50 ng/mL mEGF, 100 ng/mL mNoggin, 100 ng/mL hFGF10, 10 nM hGastrin I, 1.25 mM N-acetylcysteine, 10 mM Nicotinamide, 1x B27 supplement, RSPONDIN-1 conditioned media 10% final, WNT3A conditioned media 50% final, 100 U/mL penicillin/streptomycin, and 1x Primocin). Cells were seeded in seeded in 96-well plates and allowed to rest for 24 hours before ligand treatment where each well received 4 or 5 ligands in the compressed screen or only 1 ligand for the conventional validation screen. Assay plates were cultured for 7 days at 37°